specialti pharmaceut compani
oper two busi segment
acut segment revenue-gener
contract develop manufactur
oper contract
manufactur busi gainesvil georgia
reason report
price chang estim chang analysi
wrap reit ow-vol pt
follow straight top-lin beat miss came
surpris guidanc flattish revenu growth appear
driven headwind mylan verapamil suppli return
market disappoint equal surpris
sell-off share acknowledg quarter
result like make difficult long-term growth-ori investor
step name howev share trade ebitda
ebitda net corpor cost think share cheap
vs small molecul asset histor trade
cambrex go-priv valuat ebitda result reiter
ow-vol rate take pt
updat revenu estim mil
mil updat adj ebitda ex corpor cost
estim mil mil updat adj ep
estim
updat revenu estim mil
mil updat adj ebitda ex corpor cost
estim mil mil updat adj ep
estim
top line full year revenu million yoy
impli revenu came million yoy
estim million consensu estim
million releas manag note increas due
increas royalti recogn one compani commerci
partner increas product sale variou commerci
partner specif base busi benefit
higher revenu attribut verapamil sale
anoth manufactur verapamil provid limit
suppli market howev base commentari call
compani believ return higher level verapamil
manufactur lead lower revenu attribut
product assum backlog million translat
million new busi revenu
million headwind look forward expect core busi
rel stabl exclud headwind result
amended/extend licens suppli agreement novarti
teva lannett howev indic futur growth
driven new busi win current commerci partner
revenu top custom continu deriv
major revenu select custom teva
import disclosur analyst certif page report access current disclosur stephen
inc cover compani client may refer
lannet novarti currax acquir pernix made total revenu compar contribut
percentag total revenu vs teva decreas novarti decreas lannet
increas combin percentag includ lannet pernix look
dollar basi revenu teva million yoy revenu novarti
million yoy revenu lannet million growth yoy believ
million increas teva lannett due verapamil sale declin novarti revenu like
due taper nv focalin/ritalin sale
margin full year gross margin compar estim consensu estim
adjust ebitda margin inclus million corpor cost correspond
million yoy adj ebitda
balanc sheet/cash compani end quarter million cash million debt
balanc sheet flow oper full year million yoy
guidanc compani expect revenu rang million million flat growth y/i vs
initi estim million consensu estim million oper incom expect
rang million million vs initi estim million adj oper incom expect
rang million million vs initi estim million adj ebitda expect
rang million million million million net corpor cost vs initi estim million
thought stock follow run pristin top-lin beat reph miss disappoint guidanc came
surpris us howev even surpris declin stock view move well
overdon share trade ebitda ebitda net corpor cost think
clear valuat disconnect compar cbm share trade averag trough multipl
ultim taken privat ebitda investor public privat appetit asset
either lt outlook becom clear see lt growth investor step name
privat strateg buyer ultim interest asset take pt repres
ebitda estim ebitda net corpor cost
incom statement thousand except per share data
product sale
amort intang asset
chang warrant valuat
chang conting consider valuat
unreal gain loss avail sale secur
consolid busi net corpor cost
 revenu
gener administr revenu
pernix acquir
analyst primarili respons prepar content report certifi view express report
accur reflect analyst person view subject compani secur ii part analyst compens
directli indirectli relat specif recommend view express analyst report
